Current Report Filing (8-k)
March 02 2023 - 9:06AM
Edgar (US Regulatory)
0001642380
false
0001642380
2023-02-24
2023-02-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): February 24, 2023
Oncocyte
Corporation
(Exact
name of registrant as specified in its charter)
| California |
|
1-37648 |
|
27-1041563 |
| (State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
incorporation) |
|
File
Number) |
|
Identification
No.) |
15
Cushing
Irvine,
California 92618
(Address
of principal executive offices)
(949)
409-7600
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Exchange Act:
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common
Stock, no par value |
|
OCX |
|
The
Nasdaq Stock Market LLC |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Effective February 24, 2023,
the Board of Directors of Oncocyte Corporation (“Oncocyte” or the “Company”) appointed Joshua Riggs as Chief
Executive Officer of the Company. Mr. Riggs has also been appointed President and joined the Company’s Board of Directors
effective February 28, 2023. The compensation of Mr. Riggs was previously disclosed in a Form 8-K filed with the Securities and
Exchange Commission on December 5, 2022.
Mr. Riggs, age 40, has served
as the Company’s Interim Chief Executive Officer since December 2022. Mr. Riggs previously served as the Company’s
General Manager, Transplant from July 2022, and the Company’s Senior Director Business Development from August 2020 until September
2022. From January 2015 to August 2020, Mr. Riggs was the founder and principal of Intelliger Consulting, an organization devoted to
consumer driven healthcare, and from January 2016 to July 2020, he was a principal at Bethesda Group, LLC, a boutique consulting group
focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms to market.
There have been no transactions
with Oncocyte and there are currently no proposed transactions with Oncocyte that would require disclosure under Item 404(a) of Regulation
S-K. No arrangement or understanding exists between Mr. Riggs and any other person pursuant to which Mr. Riggs was selected as an
officer of the Company. No “family relationship,” as that term is defined in Item 401(d) of Regulation S-K, exists between
Riggs, on the one hand, and any of the Company’s directors or executive officers, on the other hand.
Item
7.01 Regulation FD Disclosure.
On March 2,
2023, Oncocyte issued a press release announcing that Mr. Riggs has been appointed as the
Company’s President and Chief Executive Officer, and that Mr. Riggs has joined the Company’s
Board of Directors. A copy of the press release is furnished as Exhibit 99.1.
The information under this Item
7.01 and the accompanying Exhibit 99.1 shall be deemed “furnished” and not “filed” under Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not
be incorporated by reference into any filings made by Oncocyte under the Securities Act of 1933, as amended, or the Exchange Act except
as may be expressly set forth by specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
ONCOCYTE CORPORATION |
| |
|
| Date:
March 2, 2023 |
By: |
/s/
Anish John |
| |
|
Anish John |
| |
|
Chief Financial Officer |
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Oct 2024 to Nov 2024
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Nov 2023 to Nov 2024
